Dec. 7, 2021 Sharon Fima, CEO and CTO, MeaTech3D:
“Today’s breakthrough is the culmination of over one year’s efforts in our cellular biology and high-throughput tissue engineering processes, as well as our precision bioprinting technology. By bioprinting a 3.67 oz steak comprised of living tissue, we believe we have both validated our core technologies and placed ourselves at the forefront of the race to develop high-end, real cell-based cultivated premium meat products.”
I think MeaTech3D has the potential to rival BYND at some point.
52 Week Range 4.81 - 11.79
Market Cap of only 84.347M
“Today’s breakthrough is the culmination of over one year’s efforts in our cellular biology and high-throughput tissue engineering processes, as well as our precision bioprinting technology. By bioprinting a 3.67 oz steak comprised of living tissue, we believe we have both validated our core technologies and placed ourselves at the forefront of the race to develop high-end, real cell-based cultivated premium meat products.”
I think MeaTech3D has the potential to rival BYND at some point.
52 Week Range 4.81 - 11.79
Market Cap of only 84.347M
BUYSELL indicators tradingindicators.store/
TRADING COURSE bit.ly/tradex
Private Signals www.patreon.com/PremiumOptionsSignals
RESULTS www.bit.ly/topgx
1%/DAY: bit.ly/3F56VTW
BYBIT partner.bybit.com/b/37880
TRADING COURSE bit.ly/tradex
Private Signals www.patreon.com/PremiumOptionsSignals
RESULTS www.bit.ly/topgx
1%/DAY: bit.ly/3F56VTW
BYBIT partner.bybit.com/b/37880